MARKET

XERS

XERS

Xeris Biopharma Holdings
NASDAQ
6.50
+0.26
+4.17%
After Hours: 6.58 +0.08 +1.22% 19:23 06/09 EDT
OPEN
6.25
PREV CLOSE
6.24
HIGH
6.54
LOW
6.25
VOLUME
1.71M
TURNOVER
--
52 WEEK HIGH
10.08
52 WEEK LOW
4.300
MARKET CAP
1.12B
P/E (TTM)
117.12
1D
5D
1M
3M
1Y
5Y
1D
Should Xeris Biopharma’s Q1 Beat and Director Stock Moves Prompt a Fresh Look From XERS Investors?
Simply Wall St · 18h ago
Savara COO Robert Lutz to take CFO role as Lowrance steps down for health reasons
PUBT · 1d ago
Weekly Report: what happened at XERS last week (0601-0605)?
Weekly Report · 1d ago
Xeris Biopharma director Barbara-Jean Anne Bormann-Kennedy sells 16,000 shares for $97,507.2
PUBT · 4d ago
Xeris Biopharma director Dawn Halkuff sells 20,000 shares worth $121,886
PUBT · 4d ago
Xeris Biopharma director John Johnson sells 15,000 shares worth $91,422
PUBT · 4d ago
Xeris Biopharma Shareholders Elect Directors and Ratify Auditor
TipRanks · 4d ago
Xeris Biopharma Chief Legal Officer Beth Hecht sells 16,667 shares for $100,980.82
PUBT · 06/02 22:05
More
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Webull offers Xeris Biopharma Holdings Inc stock information, including NASDAQ: XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.